Hyaluronic acid filler VYC-20L garners high patient satisfaction for temple hollows

Key takeaways:

• The satisfaction rate was similar across sexes (women, 84.1%; men, 70.6%) 3 months post-treatment.
• It was also similar across Fitzpatrick skin phototypes (I/III, 81.6%; III/IV, 81.1%; V/VI, 85.7%).

ORLANDO — VYC-20L hyaluronic acid injectable filler yielded high satisfaction across skin types for the treatment of temple hollowing, according to a speaker at the American Society for Dermatologic Surgery Annual Meeting.

VYC-20L is a 20 mg/mL hyaluronic acid injectable filler with lidocaine that is designed to add volume and enhance facial contour, according to a presentation by José R. Montes, MD, FACS, professor at the University of Puerto Rico School of Medicine and medical director of José Raúl Montes Eyes & Facial Rejuvenation.

“Temple hollow treatment with VYC-20L received FDA approval exactly 1 year ago,” Montes said during his presentation. “Our monthly center study demonstrated that VYC-20L is both effective and safe when injected to restore volume in the temples. The study further evaluated its impact on patient satisfaction.”

In Montes’ study, patients with all different Fitzpatrick skin phototypes who were treated with VYC-20L for temple hollowing completed a FACE-Q Satisfaction with Facial Appearance questionnaire at 3 months and 13 months post-treatment. The researchers found that patients consistently expressed high satisfaction with their results.

Compared with baseline, the overall Face-Q satisfaction scores for both facial appearance and temples were significantly higher at month 3 (P < .0001), according to the presentation.

Also, 91% of patients reported high satisfaction overall, with 89% and 91% reporting satisfaction with the look and feel of their temple area, respectively, at month 3. Similarly, 86.7% reported high satisfaction overall at 13 months post-treatment.

Eighty-seven percent of patients reported that their treatment expectations were met by month 3. In the same time frame, 98% stated they would recommend the treatment to their friends, and 93% reported that they would continue the treatment.

The positive responder rate was similar across sexes (women, 84.1%; men, 70.6%) Fitzpatrick skin phototypes (I/III, 81.6%; III/IV, 81.1%; V/VI, 85.7%) and age (< 55 years, 76.9%; 55 years, 86.8%) 3 months post-treatment.

When looking closer at the satisfaction rates across skin types, consistent rates continued to be seen in FACE-Q satisfaction with temples (I/III, 43.4%; III/IV, 43.4%; V/VI, 38.1%) and FACE-Q satisfaction with facial appearance (I/III, 24.6%; III/IV, 21.6%; V/VI, 32.4%).

“For me, this is one of the most striking aspects of the study,” Montes said. “It is rare to see such strong positive feedback across the board and it really underscores the impact VYC-20L has on improving facial and temple appearance.”